Fenbendazole and Endometrial Cancer

Fenbendazole and Endometrial Cancer: What the Research Really Shows- In recent years, fenbendazole (often shortened to “fenben”)—a veterinary anti-parasite medication—has gained attention online as a possible cancer treatment. Patient stories and social media discussions have helped fuel interest, especially among people searching for inexpensive, repurposed therapies.

But what does scientific research actually show?

This post reviews the current evidence—from laboratory studies to early clinical observations—to help patients understand where fenbendazole stands today in cancer research.

I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.

The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and cancer debate. Please scroll down the page, post a question or a comment if you have any questions.

If you’d like to learn more about repurposed drugs and cancer treatment, click now.

Thank you,

David Emerson

How Fenbendazole Could Treat Cancer (and Why It Might Not)

What Is Endometrial Cancer?

Endometrial cancer begins in the lining of the uterus (endometrium) and is the most common gynecologic cancer in developed countries.

Standard treatments include:

Surgery (hysterectomy)
Radiation therapy
Chemotherapy (advanced disease)
Hormonal therapy (selected cases)

While many patients are diagnosed early, advanced or recurrent disease can be difficult to treat, driving interest in repurposed therapies.

Why Are Patients Interested in Fenbendazole?

Fenbendazole belongs to a class of drugs called benzimidazoles, originally developed to treat parasites.

Interest in cancer comes from:

Lab evidence of tumor inhibition
Similar to chemotherapy drugs that affect microtubules
Reports of activity in drug-resistant cancers

But:
👉 Interest is based on early-stage science—not clinical proof

What Does Research Say About Fenbendazole and Endometrial Cancer?

1. Direct Evidence in Endometrial Cancer

At present:

👉 There are no high-quality studies directly testing fenbendazole in endometrial cancer patients

Most evidence must be inferred from:

Other cancers (especially gynecologic cancers)
General mechanistic studies

2. Evidence From Related Gynecologic Cancers (Ovarian Cancer)

Because ovarian and endometrial cancers share:

Hormonal influences
Molecular pathways (PI3K/AKT/mTOR, cell cycle regulation)

Researchers often look to ovarian cancer models for clues.

Key Study Findings

A preclinical study found:

Fenbendazole reduced cancer cell proliferation
Induced apoptosis (cell death)
Affected cell cycle regulation pathways

👉 Read the study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC10482585/

However, an important limitation:

Oral fenbendazole showed no tumor reduction in animal models due to poor absorption

This highlights a major issue:
👉 Bioavailability may limit real-world effectiveness

3. Mechanism: How Fenbendazole May Work

Across multiple cancer types, fenbendazole shows consistent biological effects:

A. Microtubule Disruption

Prevents cancer cells from dividing
Similar to taxane chemotherapy

👉 Fenbendazole disrupts microtubule polymerization

B. Cell Cycle Arrest (G2/M Phase)

Stops replication of cancer cells

👉 Demonstrated in resistant cancer cell lines

C. Apoptosis (Programmed Cell Death)

Activates cancer cell self-destruction pathways

D. Metabolic Disruption

May reduce glucose uptake and increase oxidative stress

👉 Review:
https://pubmed.ncbi.nlm.nih.gov/39197912/

E. Cancer Stem Cell Effects

May target cells responsible for recurrence

👉 Benzimidazoles may affect cancer stem cells

4. Evidence From Drug-Resistant Cancer Models

One important area of research:

Fenbendazole showed activity in chemotherapy-resistant cancer cells

👉 Read the study:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9437363/

Key finding:

Induced apoptosis and cell cycle arrest even in resistant cells

Why this matters for endometrial cancer:

Advanced cases often become chemotherapy-resistant

The Problem: No Human Clinical Evidence

Despite promising mechanisms:

No randomized trials in endometrial cancer
No established dosing or safety in oncology patients
Limited and inconsistent animal data

A 2025 review summarized the issue clearly:

👉 Fenbendazole shows promise in preclinical studies, but
clinical evidence is currently limited

Safety Concerns

Fenbendazole:

Is not FDA-approved for cancer treatment in humans
Has unknown long-term safety in oncology patients
May have liver and metabolic effects

Additionally:

Poor absorption may lead to ineffective or unpredictable dosing

Integrative Oncology Perspective (PeopleBeatingCancer Approach)

Rather than relying on one experimental drug, evidence supports a multi-therapy strategy.

Evidence-Based Complementary Approaches for Endometrial Cancer

Weight management (strong risk factor)
Anti-inflammatory diet (Mediterranean-style)
Physical activity (improves survival)
Blood sugar control (important in hormonally driven cancers)
Vitamin D optimization
Curcumin (anti-inflammatory, anti-proliferative)
Green tea extract (EGCG)
Mind-body therapies (stress reduction)

These approaches:

Have human data
Improve outcomes and quality of life
May reduce recurrence risk

Should Endometrial Cancer Patients Use Fenbendazole?

Potential Pros

Strong biological rationale
Activity in lab and animal models
Possible effects in resistant cancer

Major Cons

No human clinical validation
Bioavailability issues
Unknown safety profile
Risk of delaying effective therapy

Key Takeaways

Fenbendazole is a veterinary anti-parasitic drug being explored for anti-cancer properties
There are no direct human clinical trials in endometrial cancer
Evidence comes from preclinical studies and related gynecologic cancers (especially ovarian)
Mechanisms include microtubule disruption, apoptosis, and metabolic interference
Fenbendazole remains experimental and unproven for endometrial cancer

Bottom Line

Fenbendazole is:

Biologically interesting
Preclinically promising
Clinically unproven

For endometrial cancer patients:

👉 The evidence supports:

Standard-of-care therapy
Combined with evidence-based integrative strategies
Not reliance on unproven drugs alone

Evidence Appendix (PubMed + Primary Sources)

Final Thought

Fenbendazole fits a familiar pattern in oncology:

Compelling in theory, incomplete in practice

For endometrial cancer survivors, the goal is not chasing unproven therapies—
it’s building a comprehensive, evidence-based survivorship plan.

To Learn More About Repurposed Drugs for Cancer-

Fenbendazole and Endometrial Cancer Fenbendazole and Endometrial Cancer Fenbendazole and Endometrial Cancer

Our Mission